Srilatha Tangada

745 total citations
27 papers, 585 citations indexed

About

Srilatha Tangada is a scholar working on Hematology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Srilatha Tangada has authored 27 papers receiving a total of 585 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Hematology, 4 papers in Pulmonary and Respiratory Medicine and 4 papers in Oncology. Recurrent topics in Srilatha Tangada's work include Hemophilia Treatment and Research (19 papers), Platelet Disorders and Treatments (10 papers) and Blood Coagulation and Thrombosis Mechanisms (7 papers). Srilatha Tangada is often cited by papers focused on Hemophilia Treatment and Research (19 papers), Platelet Disorders and Treatments (10 papers) and Blood Coagulation and Thrombosis Mechanisms (7 papers). Srilatha Tangada collaborates with scholars based in United States, Poland and United Kingdom. Srilatha Tangada's co-authors include Harvey A. Schenkein, Keisuke Nakashima, John G. Tew, Jibo Zhang, Chin‐Lo Hahn, Suzanne E. Barbour, Oleksandra Stasyshyn, Bruce M. Ewenstein, Vasily Mamonov and Sandra Vallin Antunes and has published in prestigious journals such as Blood, Journal of Periodontology and Biochimica et Biophysica Acta (BBA) - Molecular Cell Research.

In The Last Decade

Srilatha Tangada

24 papers receiving 553 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Srilatha Tangada United States	10	268	211	87	71	59	27	585
F Giovine Italy	5	79 0.3×	43 0.2×	38 0.4×	4 0.1×	33 0.6×	9	359
H Barrière France	9	34 0.1×	30 0.1×	26 0.3×	27 0.4×	10 0.2×	86	295
M. Önder Türkiye	11	50 0.2×	29 0.1×	35 0.4×	3 0.0×	17 0.3×	15	500
Mualla Polat Türkiye	11	18 0.1×	32 0.2×	28 0.3×	4 0.1×	41 0.7×	36	374
D. Sotiriadis Greece	14	21 0.1×	14 0.1×	42 0.5×	34 0.5×	17 0.3×	27	411
Himmet Haluk Akar Türkiye	10	42 0.2×	8 0.0×	39 0.4×	11 0.2×	9 0.2×	34	268
Zhongming Zhang China	10	81 0.3×	3 0.0×	38 0.4×	51 0.7×	30 0.5×	27	375
Karima Senouci Morocco	9	17 0.1×	12 0.1×	20 0.2×	30 0.4×	6 0.1×	131	295
Parvaneh Hatami Iran	11	46 0.2×	14 0.1×	16 0.2×	54 0.8×	8 0.1×	58	352
Jonathan Aldridge Sweden	8	5 0.0×	104 0.5×	29 0.3×	9 0.1×	34 0.6×	11	273

Countries citing papers authored by Srilatha Tangada

Since Specialization

Citations

This map shows the geographic impact of Srilatha Tangada's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Srilatha Tangada with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Srilatha Tangada more than expected).

Fields of papers citing papers by Srilatha Tangada

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Srilatha Tangada. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Srilatha Tangada. The network helps show where Srilatha Tangada may publish in the future.

Co-authorship network of co-authors of Srilatha Tangada

This figure shows the co-authorship network connecting the top 25 collaborators of Srilatha Tangada. A scholar is included among the top collaborators of Srilatha Tangada based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Srilatha Tangada. Srilatha Tangada is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mascher, Daniel, et al.. (2025). Evaluation of Plasma Polyethylene Glycol (PEG) Levels in a Healthy Adult Population. International Journal of Toxicology. 44(6). 451–457.

Manon‐Jensen, Tina, Srilatha Tangada, Cecilie L. Bager, et al.. (2023). Evaluation of collagen turnover biomarkers as an objective measure for efficacy of treatment with rurioctocog alfa pegol in patients with hemophilia A: a secondary analysis of a randomized controlled trial. Journal of Thrombosis and Haemostasis. 22(1). 90–100. 4 indexed citations

Sidonio, Robert F., Alexis A. Thompson, Flora Peyvandi, et al.. (2023). Immunogenicity, safety, and efficacy of rurioctocog alfa pegol in previously untreated patients with severe hemophilia A: interim results from a phase 3, prospective, multicenter, open-label study. Expert Review of Hematology. 16(10). 793–801. 4 indexed citations

Escuriola‐Ettingshausen, C., Robert Klamroth, Miguel A. Escobar, et al.. (2023). Targeting an elevated FVIII level using personalized rurioctocog alfa pegol prophylaxis in specific patient populations with hemophilia A: post hoc subanalysis of the randomized, phase 3 PROPEL study. Therapeutic Advances in Hematology. 14. 1564096356–1564096356.

Sidonio, Robert F., Christine Knoll, Flora Peyvandi, et al.. (2021). Immunogenicity, Efficacy and Safety of Rurioctocog Alfa Pegol in Previously Untreated Patients with Severe Hemophilia a: Interim Results from an Open-Label Multicenter Clinical Trial. Blood. 138(Supplement 1). 3184–3184. 3 indexed citations

Sidonio, Robert F., Alexis A. Thompson, Flora Peyvandi, et al.. (2021). Rurioctocog Alfa Pegol Use in Immune Tolerance Induction: Interim Results from an Open-Label Multicenter Clinical Trial in Previously Untreated Patients with Severe Hemophilia a. Blood. 138(Supplement 1). 3185–3185. 1 indexed citations

Windyga, Jerzy, Margarita Timofeeva, Oleksandra Stasyshyn, et al.. (2020). Phase 3 Clinical Trial: Perioperative Use of Nonacog Gamma, a Recombinant Factor IX, in Previously Treated Patients With Moderate/Severe Hemophilia B. Clinical and Applied Thrombosis/Hemostasis. 26. 2874345367–2874345367.

Chowdary, Pratima, Eric S. Mullins, Barbara A. Konkle, et al.. (2020). Long‐term safety and efficacy results from the phase 3b, open‐label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A. Haemophilia. 26(4). e168–e178. 19 indexed citations

Windyga, Jerzy, Oleksandra Stasyshyn, Toshko Lissitchkov, et al.. (2020). Safety, Immunogenicity, and Hemostatic Efficacy of Nonacog Gamma in Patients With Severe or Moderately Severe Hemophilia B: A Continuation Study. Clinical and Applied Thrombosis/Hemostasis. 26. 2874349364–2874349364. 1 indexed citations

10.

Gruppo, Ralph A., et al.. (2019). Perioperative haemostasis with full‐length, PEGylated, recombinant factor VIII with extended half‐life (rurioctocog alfa pegol) in patients with haemophilia A: Final results of a multicentre, single‐arm phase III trial. Haemophilia. 25(5). 773–781. 26 indexed citations

11.

Baek, Hee Jo, Sang Kyu Park, Young Shil Park, et al.. (2019). Subgroup analysis of a phase 2/3 study of rurioctocog alfa pegol in patients with severe hemophilia A: efficacy and safety in previously treated Korean patients. Blood Research. 54(3). 198–203. 3 indexed citations

12.

Mullins, Eric S., Barbara A. Konkle, Catherine McGuinn, Werner Engl, & Srilatha Tangada. (2018). Efficacy and Safety Results from a Phase 3b, Open-Label, Multicenter, Continuation Study of Rurioctocog Alfa Pegol for Prophylaxis in Previously Treated Patients with Severe Hemophilia A. Blood. 132(Supplement 1). 2483–2483. 1 indexed citations

13.

Turecek, Peter L., Srilatha Tangada, Herbert Gritsch, et al.. (2015). Nonacog gamma, a novel recombinant factor IX with low factor IXa content for treatment and prophylaxis of bleeding episodes. Expert Review of Clinical Pharmacology. 8(2). 163–177. 6 indexed citations

14.

Stasyshyn, Oleksandra, Sandra Vallin Antunes, Vasily Mamonov, et al.. (2014). Prophylaxis with anti‐inhibitor coagulant complex improves health‐related quality of life in haemophilia patients with inhibitors: results from FEIBA NF Prophylaxis Study. Haemophilia. 20(5). 644–650. 23 indexed citations

15.

Antunes, Sandra Vallin, Srilatha Tangada, Oleksandra Stasyshyn, et al.. (2013). Randomized comparison of prophylaxis and on‐demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors. Haemophilia. 20(1). 65–72. 94 indexed citations

16.

Tangada, Srilatha, Joseph V. Califano, Keisuke Nakashima, et al.. (1997). The Effect of Smoking on Serum IgG2 Reactive With Actinobacillus actinomycetemcomitans in Early‐Onset Periodontitis Patients. Journal of Periodontology. 68(9). 842–850. 56 indexed citations

17.

Tew, John G., Stephen Quinn, Srilatha Tangada, et al.. (1996). Antibody of the IgG2 Subclass, Actinobacillus actinomycetemcomitans, and Early‐Onset Periodontitis. Journal of Periodontology. 67(3S). 317–322. 20 indexed citations

18.

Tangada, Srilatha, Raymond D. A. Peterson, & Jane D. Funkhouser. (1995). Regulation of expression of aminopeptidase N in fetal rat lung by dexamethasone and epidermal growth factor. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1268(2). 191–199. 8 indexed citations

19.

Funkhouser, Jane D., Srilatha Tangada, & Raymond D. A. Peterson. (1991). Ectopeptidases of alveolar epithelium: candidates for roles in alveolar regulatory mechanisms. American Journal of Physiology-Lung Cellular and Molecular Physiology. 260(6). L381–L385. 10 indexed citations

20.

Funkhouser, Jane D., et al.. (1991). p146 type II alveolar epithelial cell antigen is identical to aminopeptidase N. American Journal of Physiology-Lung Cellular and Molecular Physiology. 260(4). L274–L279. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact